Therapeutic advances in chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue SUPPL., 2004, Pages

  Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMINOTRANSFERASE; HEPATITIS B ANTIGEN; HEPATITIS E ANTIGEN; LAMIVUDINE; VIRUS DNA;

CLINICAL TRIAL; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; HEPATITIS B; HUMAN; JAUNDICE; LABORATORY TEST; LIVER CIRRHOSIS; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LONG TERM CARE; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SEROCONVERSION; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS MUTANT;

EID: 1542407372     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2003.03391.x     Document Type: Review

References (11)

1. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. New Eng J. Med. 1998; 339: 61-8.
2. Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2001; 16 (Suppl.): A60.
3. Schiff ER, Heathcote J, Dienstag JL et al. Improvements in liver histology and cirrhosis with extended lamivudine therapy. Hepatology 2000; 32: 296A (Abstract 546).
4. Leung NW, Liaw YF, Chang TT et al. Durable HBeAg response in Chinese patients treated with lamivudine. Hepatology 2001; 34: 348A (Abstract 705).
5. Schiff ER, Cianciara J, Karavalein S et al. Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B (CHB). Hepatology 2000; 32: 99 (Abstract P/C06/12).
6. Hong SP, Han KH, Ahn SH et al. Additional lamivudine therapy after HBeAg seroconversion would prolong the durability of response in HBV endemic area. Hepatology 2001; 34: 322A (Abstract 600).
7. Korenman K, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med. 1991; 114: 629-34.
8. Esteban R, Goldin RD, Tassopoulos NC et al. Clinical & histological outcome of extended lamivudine in patients with HBeAg-negative chronic hepatitis B. Hepatology 2001; 34: 446A (Abstract 1097).
9. Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-10.
10. Perrillo R, Schiff E, Hann H et al. The addition of adevofir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine - preliminary 24 week results. Hepatology 2000; 34: 349A (Abstract 708.
11. Lai CL, Maddrey WC, Marr C, Woessner M, Atkins M. Long-term safety of lamivudine in patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): 1208 (Abstract P-H-70).